Articles published by Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
June 17, 2024
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
June 06, 2024
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2024
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024
Via Business Wire
Tickers
MIRM
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
January 08, 2024
Via Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
Via Business Wire
Tickers
MIRM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.